ArticlePloS one2011
Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05411744 (One-month Latent Tuberculosis Treatment for Renal Transplant Candidates), which is not on this map. Cited by 9 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
One-month Latent Tuberculosis Treatment for Renal Transplant Candidates
Who cites it
9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review.BMC public health · 2022Pooled it
- Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.The Cochrane database of systematic reviews · 2013Pooled it
- Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial.Annals of internal medicine · 2017Trial
- US Guidelines Fall Short on Short-Course Tuberculosis-Preventive Therapy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- The Global Expansion of LTBI Screening and Treatment Programs: Exploring Gaps in the Supporting Economic Evidence.Pathogens (Basel, Switzerland) · 2023Review
- Cost effectiveness of three months of rifapentine and isoniazid for latent tuberculosis in Syrian refugees.Journal of clinical tuberculosis and other mycobacterial diseases · 2021Article
- Optimizing the Design of Latent Tuberculosis Treatment Trials: Insights from Mathematical Modeling.American journal of respiratory and critical care medicine · 2020Article
- Activism on rifapentine pricing: removing cost barriers to improve the uptake of tuberculosis research innovations.Public health action · 2014Article
- House calls by community health workers and public health nurses to improve adherence to isoniazid monotherapy for latent tuberculosis infection: a retrospective study.BMC public health · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
rationaleRifapentine-based regimens for treating latent tuberculosis infection (LTBI) are being considered for future clinical trials, but even if they prove effective, high drug costs may limit their economic viability.
objectivesTo inform clinical trial design by estimating the potential costs and effectiveness of rifapentine-based regimens for treatment of latent tuberculosis infection (LTBI).
methodsWe used a Markov model to estimate cost and societal benefits for three regimens for treating LTBI: Isoniazid/rifapentine daily for one month, isoniazid/rifapentine weekly for three months (self-administered and directly-observed), and isoniazid daily for nine months; a strategy of "no treatment" used for comparison. Costs, quality-adjusted life-years gained, and instances of active tuberculosis averted were calculated for all arms.
resultsBoth daily isoniazid/rifapentine for one month and weekly isoniazid/rifapentine for three months were less expensive and more effective than other strategies under a wide variety of clinically plausibly parameter estimates. Daily isoniazid/rifapentine for one month was the least expensive and most effective regimen.
conclusionsDaily isoniazid/rifapentine for one month and weekly isoniazid/rifapentine for three months should be studied in a large-scale clinical trial for efficacy. Because both regimens performed well even if their efficacy is somewhat reduced, study designers should consider relaxing non-inferiority boundaries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.